Kuros Biosciences AG (CSBTF)
Kuros Biosciences Statistics
Share Statistics
Kuros Biosciences has 38.11M shares outstanding. The number of shares has increased by 2.32% in one year.
| Shares Outstanding | 38.11M |
| Shares Change (YoY) | 2.32% |
| Shares Change (QoQ) | 0.6% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 35.82M |
| Failed to Deliver (FTD) Shares | - |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -205.09 and the forward PE ratio is null. Kuros Biosciences's PEG ratio is 2.78.
| PE Ratio | -205.09 |
| Forward PE | n/a |
| PS Ratio | 10.09 |
| Forward PS | n/a |
| PB Ratio | 12.97 |
| P/FCF Ratio | 375.79 |
| PEG Ratio | 2.78 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Kuros Biosciences.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.14, with a Debt / Equity ratio of 0.03.
| Current Ratio | 2.14 |
| Quick Ratio | 1.69 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | -3.2 |
| Debt / FCF | 0.88 |
| Interest Coverage | -33.52 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $619.3K |
| Profits Per Employee | $-30.46K |
| Employee Count | 122 |
| Asset Turnover | 0.89 |
| Inventory Turnover | 1.43 |
Taxes
| Income Tax | 370K |
| Effective Tax Rate | -11.06% |
Stock Price Statistics
The stock price has increased by 356.34% in the last 52 weeks. The beta is 0.59, so Kuros Biosciences's price volatility has been higher than the market average.
| Beta | 0.59 |
| 52-Week Price Change | 356.34% |
| 50-Day Moving Average | 23.77 |
| 200-Day Moving Average | 23.1 |
| Relative Strength Index (RSI) | 85.5 |
| Average Volume (20 Days) | 558 |
Income Statement
In the last 12 months, Kuros Biosciences had revenue of 75.56M and earned -3.72M in profits. Earnings per share was -0.1.
| Revenue | 75.56M |
| Gross Profit | 62.03M |
| Operating Income | -5M |
| Net Income | -3.72M |
| EBITDA | -561K |
| EBIT | -3.2M |
| Earnings Per Share (EPS) | -0.1 |
Balance Sheet
The company has 17.46M in cash and 1.79M in debt, giving a net cash position of 15.67M.
| Cash & Cash Equivalents | 17.46M |
| Total Debt | 1.79M |
| Net Cash | 15.67M |
| Retained Earnings | -45.43M |
| Total Assets | 84.54M |
| Working Capital | 23.86M |
Cash Flow
In the last 12 months, operating cash flow was 3.14M and capital expenditures -1.11M, giving a free cash flow of 2.03M.
| Operating Cash Flow | 3.14M |
| Capital Expenditures | -1.11M |
| Free Cash Flow | 2.03M |
| FCF Per Share | 0.05 |
Margins
Gross margin is 82.1%, with operating and profit margins of -6.61% and -4.92%.
| Gross Margin | 82.1% |
| Operating Margin | -6.61% |
| Pretax Margin | -4.43% |
| Profit Margin | -4.92% |
| EBITDA Margin | -0.74% |
| EBIT Margin | -6.61% |
| FCF Margin | 2.68% |
Dividends & Yields
CSBTF does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
Currently there are no analyst rating for CSBTF.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Oct 12, 2020. It was a forward split with a ratio of 217:200.
| Last Split Date | Oct 12, 2020 |
| Split Type | forward |
| Split Ratio | 217:200 |
Scores
| Altman Z-Score | 24.12 |
| Piotroski F-Score | 3 |